2. Search Result
Search Result
Results for "

drug-resistant bacteria

" in MedChemExpress (MCE) Product Catalog:

71

Inhibitors & Agonists

2

Screening Libraries

2

Biochemical Assay Reagents

13

Peptides

11

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16566A
    Kanamycin sulfate
    25+ Cited Publications

    Kanamycin A sulfate

    		 Bacterial Antibiotic Infection
    Kanamycin (Kanamycin A) sulfate is an orally active antibacterial (gram-negative/positive bacteria) agent, inhibits translocation and causes misencoding by binding to the 70 S ribosomal subunit. Kanamycin sulfate shows good inhibitory activity to both M. tuberculosis (sensitive and drug-resistant ) and K. pneumonia, which can be used in studies of tuberculosis and pneumonia .
    Kanamycin sulfate
  • HY-16566
    Kanamycin
    25+ Cited Publications

    Kanamycin A

    		 Antibiotic Bacterial Infection Inflammation/Immunology
    Kanamycin (Kanamycin A) is an orally active antibacterial (gram-negative/positive bacteria) agent, inhibits translocation and causes misencoding by binding to the 70 S ribosomal subunit. Kanamycin shows good inhibitory activity to both M. tuberculosis (sensitive and drug-resistant ) and K. pneumonia, which can be used in studies of tuberculosis and pneumonia .
    Kanamycin
  • HY-A0256
    Clavulanic acid
    5+ Cited Publications

    		 Beta-lactamase Antibiotic Bacterial Infection Inflammation/Immunology
    Clavulanic acid is a naturally occurring powerful bacterial β-lactamases inhibitor for research of infections caused by bacteria, including infections of the ears. Clavulanic acid is active against a wide spectrum of gram-positive and gram-negative bacterias .
    Clavulanic acid
  • HY-117974
    Durlobactam sodium
    5+ Cited Publications

    ETX2514

    		 Bacterial Infection
    Durlobactam sodium salt (ETX2514) is a broad-spectrum β-lactamase inhibitor with IC50s of 4, 14 and 190 nM for Class A KPC-2, Class C AmpC and Class D OXA-24, respectively. For the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii .
    Durlobactam sodium
  • HY-W016420
    Fosfomycin sodium
    10+ Cited Publications

    MK-0955 sodium

    		 Bacterial Antibiotic Infection Cancer
    Fosfomycin (MK-0955) sodium is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin sodium shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria .
    Fosfomycin sodium
  • HY-P1939
    Cyclo(L-Leu-L-Pro)

    Cyclo(L-prolyl-L-leucyl)

    		 Fungal Bacterial Influenza Virus Infection
    Cyclo(L-Leu-L-Pro) is a cyclic dipeptide with broad-spectrum antibacterial, antiviral and antifungal activities. Its biological activity is highly dependent on the stereoconfiguration and is widely present in microbial metabolites. Cyclo(L-Leu-L-Pro) efficiently and specifically inhibits the production of aflatoxin by Aspergillus flavus. The cis configuration of Cyclo(L-Leu-L-Pro) (cis-cyclo(L-Leu-L-Pro)) has broad-spectrum antibacterial activity against multi-drug resistant bacteria and significantly inhibits the influenza A virus H3N2 .
    Cyclo(L-Leu-L-Pro)
  • HY-B1075
    Fosfomycin calcium
    10+ Cited Publications

    MK-​0955 calcium

    		 Bacterial Antibiotic Infection Cancer
    Fosfomycin (MK-0955) calcium is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin calcium shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria .
    Fosfomycin calcium
  • HY-B1075A
    Fosfomycin

    MK-0955

    		 Bacterial Antibiotic Infection Cancer
    Fosfomycin (MK-0955) is a broad-spectrum antibiotic. Fosfomycin can cross blood-brain barrier penetrating, and irreversibly inhibits an early stage in cell wall synthesis. Fosfomycin shows anti-bacteria activity for a range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria .
    Fosfomycin
  • HY-B0609
    Fosfomycin tromethamine
    10+ Cited Publications

    MK-0955 tromethamine

    		 Bacterial Antibiotic Infection Cancer
    Fosfomycin (MK-0955) tromethamine is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin tromethamine shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria .
    Fosfomycin tromethamine
  • HY-P2460
    SMAP-29

    		Bacterial Fungal Interleukin Related TNF Receptor Infection Inflammation/Immunology
    SMAP‑29 is a cathelicidin antimicrobial peptide with LPS‑binding and anti‑inflammatory properties. SMAP‑29 exerts broad‑spectrum antimicrobial activity against bacteria, fungi and multidrug‑resistant isolates. SMAP‑29 kills pathogens by permeabilizing bacterial membranes, inducing depolarization and cell lysis, and also inhibits inflammatory cytokines while reducing lethality in septic shock and pneumonia models. SMAP-29 can be used for research on bacterial infections, drug-resistant infections, septic shock .
    SMAP-29
  • HY-W040128
    Kanamycins sulfate

    		Antibiotic Autophagy JNK Bcl-2 Family Infection
    Kanamycins sulfate is a blood-brain barrier-permeable JNK1 and Bcl-2 modulator as well as an antibiotic, with broad-spectrum antibacterial, and biofilm-inhibiting activities, and it induces autophagy. Kanamycins sulfate promotes Bcl-2 phosphorylation to upregulate autophagy levels, triggering changes such as mitochondrial swelling and endoplasmic reticulum expansion. Consequently, it causes reversible neuronal damage in the dorsal cochlear nucleus without inducing significant neuronal apoptosis. In the presence of exogenous alanine or glucose, Kanamycins sulfate effectively kills drug-resistant bacteria, restores drug sensitivity of multidrug-resistant bacteria, and alleviates urinary tract and kidney infections in mice. Kanamycins sulfate can be applied to scientific research related to Mycobacterium tuberculosis, salmonellosis, brucellosis, shigellosis, urinary tract infections, and reversible neurotoxicity .
    Kanamycins sulfate
  • HY-125576
    Griselimycin

    		Bacterial Infection
    Griselimycin is a cyclic lipopeptide produced by Streptomyces. Griselimycin specifically binds to the sliding clamp of bacterial DNA polymerase and does not interact with human PCNA. Griselimycin exhibits potent antibacterial activity against Mycobacterium tuberculosis (including drug-resistant strains) and a variety of Gram-negative bacteria .
    Griselimycin
  • HY-W984782
    Flindersine

    		GLUT Bacterial Fungal AMPK PPAR Reactive Oxygen Species (ROS) Apoptosis SOD Infection Metabolic Disease Cancer
    Flindersine is an alkaloid with multiple activities including antibacterial, antifungal, antitumor, and antidiabetic properties. Flindersine increases the activity of antioxidant enzymes, restores the levels of renal biomarkers, and reduces blood glucose, blood lipid, and insulin levels in diabetic rats. Flindersine inhibits the growth of Gram-positive bacteria, Gram-negative bacteria, drug-resistant bacteria, as well as dermatophytes, filamentous fungi, and yeasts. Flindersine reduces the viability of cancer cells and induces apoptosis. Flindersine can be used in research related to breast cancer, type 2 diabetes, bacterial infections, and fungal infections .
    Flindersine
  • HY-P10233A
    SAAP 148 TFA

    		Bacterial Infection
    SAAP 148 TFA is a synthetic antimicrobial peptide (bacteria) that interacts with and disrupts the lipid bilayer of bacterial cytoplasmic membranes, thereby inducing changes in membrane permeability and bacterial death. SAAP 148 TFA kills drug-resistant, multidrug-resistant and persister bacterial strains, inhibits biofilm formation, eliminates established biofilms, and blocks bacterial colonization on implant surfaces. SAAP 148 TFA retains its activity after modification or immobilization, exhibits variable cytotoxicity in different human cell models, and shows reduced efficacy in protein-rich environments. SAAP 148 TFA can be used in infection-related research .
    SAAP 148 TFA
  • HY-103249
    Reutericyclin

    Reutericycline

    		 Bacterial Infection Metabolic Disease
    Reutericyclin (Reutericycline) is an orally active antibacterial and anti-obesity agent that selectively inhibits Gram-positive bacteria. By selectively dissipating transmembrane potential, Reutericyclin exerts non-lytic bactericidal or bacteriostatic activity against pathogens such as Clostridium difficile and Staphylococcus aureus, and rapidly kills vegetative cells and spores of Clostridium difficile. Reutericyclin possesses favorable properties including resistance to enzymatic hydrolysis, iron-chelating function, and poor absorption by colonic epithelium. Reutericyclin not only eradicates staphylococcal biofilms and inhibits drug-resistant strains, but also counteracts Risperidone (HY-11018)-induced weight gain by inducing changes in gut microbiota composition and restoring energy utilization efficiency. Reutericyclin can be used in research related to Clostridium difficile infection, Risperidone-induced weight gain, and staphylococcal superficial skin infections .
    Reutericyclin
  • HY-162959
    BWC0977

    		Bacterial Topoisomerase DNA/RNA Synthesis Infection
    BWC0977 is an antibacterial agent that inhibits bacterial DNA replication via inhibition of DNA gyrase and topoisomerase IV. BWC0977 exhibits a minimum inhibitory concentration (MIC90) of 0.03-2 µg/mL against MDR (Multi-Drug Resistant) Gram-negative bacteria .
    BWC0977
  • HY-151102
    Fabimycin

    		Antibiotic Bacterial Infection
    Fabimycin is a FabI inhibitor with potent antibacterial activity against gram-negative bacteria. Fabimycin is effective against drug-resistant gram-negative Infections in vivo .
    Fabimycin
  • HY-135748A
    Poly (I:C):Kanamycin (1:1) sodium
    Maximum Cited Publications
    56 Publications Verification

    		 RIG-I-like receptor (RLR) Toll-like Receptor (TLR) Apoptosis Infection Cancer
    Poly (I:C):Kanamycin (1:1) sodium is an isometric complex of Poly (I:C) (HY-135748) and Kanamycin (HY-16566). Poly(I:C) sodium, a synthetic analog of double-stranded RNA, is a TLR3 and retinoic acid-inducible gene I receptor (RIG-I and b>MDA5) agonist. Poly(I:C) sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses and induce apoptosis in cancer cells . Kanamycin is an orally active antibacterial agent (Gram-negative/positive bacteria) that inhibits translocation and causes miscoding by binding to the 70S ribosomal subunit. Kanamycin shows good inhibitory activity against Mycobacterium tuberculosis (susceptible and drug-resistant) and Klebsiella pneumoniae, and can be used in the research of tuberculosis and pneumonia .
    Poly (I:C):Kanamycin (1:1) sodium
  • HY-N14107
    Cinnabarin

    		Bacterial Endogenous Metabolite Infection
    Cinnabarin is a natural phenoxazinone red pigment derived from Pycnoporus sanguineus. Cinnabarin reduces rabies virus infection levels in neuroblastoma cells and causes cytopathic effects on neuroblastoma cell monolayers at high concentrations. Cinnabarin exhibits antibacterial activity against bacteria, with a preference for Gram-positive bacteria and human isolates. Cinnabarin can be used in studies related to rabies and drug-resistant Gram-positive bacteria .
    Cinnabarin
  • HY-177716
    Ciprofloxacin prodrug-1

    		Beta-lactamase Bacterial Infection
    Ciprofloxacin prodrug-1 (Compound 35) is an activated prodrug of β-lactase. Ciprofloxacin prodrug-1 exhibits good antibacterial activity against bacteria containing β-lactase (MIC = 63 nM). After being hydrolyzed by β-lactase, Ciprofloxacin prodrug-1 can release Ciprofloxacin (HY-B0356), thereby inhibiting the activity of DNA gyrase. Ciprofloxacin prodrug-1 can be used to study infections caused by enzyme-producing drug-resistant bacteria (such as uropathogenic Escherichia coli) .
    Ciprofloxacin prodrug-1
  • HY-P10233
    SAAP 148

    		Bacterial Infection
    SAAP 148 is a synthetic antimicrobial peptide (bacteria) that interacts with and disrupts the lipid bilayer of bacterial cytoplasmic membranes, thereby inducing changes in membrane permeability and bacterial death. SAAP 148 kills drug-resistant, multidrug-resistant and persister bacterial strains, inhibits biofilm formation, eliminates established biofilms, and blocks bacterial colonization on implant surfaces. SAAP 148 retains its activity after modification or immobilization, exhibits variable cytotoxicity in different human cell models, and shows reduced efficacy in protein-rich environments. SAAP 148 can be used in infection-related research .
    SAAP 148
  • HY-172734
    FG-2101

    		Bacterial Infection
    FG-2101 is a selective and orally active non-hydroxamate LpxC inhibitor with an IC50 of ~1 nM. FG-2101 exhibits exquisite selectivity over other bacterial and human metalloenzymes. FG-2101 can be used for the study of Gram-negative bacteria infections including drug-resistant strains .
    FG-2101
  • HY-186019
    FtsZ-IN-14

    		Bacterial Infection
    FtsZ-IN-14 (example XI) is a filamentous temperature-sensitive protein Z (FtsZ) inhibitor. FtsZ-IN-14 can inhibit the growth of various drug-resistant bacteria in vitro and can be used to prepare antibiotics against drug-resistant bacteria .
    FtsZ-IN-14
  • HY-16566R
    Kanamycin (Standard)

    Kanamycin A (Standard)

    		 Reference Standards Antibiotic Bacterial Infection Inflammation/Immunology
    Kanamycin (Standard) is the analytical standard of Kanamycin. This product is intended for research and analytical applications. Kanamycin (Kanamycin A) is an orally active antibacterial (gram-negative/positive bacteria) agent, inhibits translocation and causes misencoding by binding to the 70 S ribosomal subunit. Kanamycin shows good inhibitory activity to both M. tuberculosis (sensitive and drug-resistant ) and K. pneumonia, which can be used in studies of tuberculosis and pneumonia[1][2][3][4].
    Kanamycin (Standard)
  • HY-178347
    Debio 1453

    		Bacterial Infection
    Debio 1453 is a bactericidal FabI inhibitor potent against N. gonorrhoeae (IC50 = 0.6 nM), including drug-resistant strains. Debio 1453 demonstrates a low propensity for resistance selection and is effective in eradicating both planktonic and intracellular bacteria through a mechanism of concurrently inhibiting FabI and engaging the non-mutable NADH cofactor. Debio 1453 clears antibiotic-resistant N. gonorrhoeae infection in a murine vaginal model. Debio 1453 can be used for gonorrhoea research .
    Debio 1453
  • HY-125356
    ETX0282

    		Beta-lactamase Infection
    ETX0282 is an orally active prodrug, with its active form being ETX1317. ETX0282 and ETX1317 are β-lactamase inhibitors of the dioxolane-dibenzo-p-heptane (DBO) type. ETX0282 exhibits high stability during intestinal absorption and can be efficiently converted into ETX1317 in the liver. ETX0282 alone has no bactericidal activity, but in a mouse model of neutropenic thigh infection, it can significantly reduce bacterial load when used in combination with Cefpodoxime Proxetil (HY-N7101). ETX0282 can be used for the study of infections caused by drug-resistant Gram-negative bacteria .
    ETX0282
  • HY-B1075AS
    (Rac)-Fosfomycin (benzylamine)-13C3

    MK-0955 (benzylamine)-13C3

    		 Bacterial Antibiotic Infection
    (Rac)-Fosfomycin (benzylamine)- 13C3 is the 13C labeled Fosfomycin . Fosfomycin (MK-0955) is a broad-spectrum antibiotic. Fosfomycin can cross blood-brain barrier penetrating, and irreversibly inhibits an early stage in cell wall synthesis. Fosfomycin shows anti-bacteria activity for a range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria .
    (Rac)-Fosfomycin (benzylamine)-13C3
  • HY-B1075R
    Fosfomycin calcium (Standard)

    MK-​0955 calcium (Standard)

    		 Reference Standards Bacterial Antibiotic Infection Cancer
    Fosfomycin (calcium) (Standard) is the analytical standard of Fosfomycin (calcium). This product is intended for research and analytical applications. Fosfomycin (MK-0955) calcium is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin calcium shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria .
    Fosfomycin calcium (Standard)
  • HY-178504
    Lug-15

    		Bacterial Infection
    Lug-15 is a rapid bactericidal agent. Lug-15 exhibits strong antibacterial activity against both Gram-positive and Gram-negative bacteria, including drug-resistant strains. Lug-15 rapidly kills bacteria primarily through membrane disruption and had a very low propensity to induce bacterial resistance. Lug-15 demonstrates low hemolytic toxicity and significant therapeutic potential in various infection models. Lug-15 can be used for research on combating infections caused by multi-drug resistant bacteria .
    Lug-15
  • HY-105048A
    Omiganan pentahydrochloride

    		Bacterial Infection
    Omiganan pentahydrochloride is a cationic peptide compound with a broad antibacterial profile. Omiganan pentahydrochloride is capable of inhibiting a variety of bacteria, including yeast, and is active against both gram-positive and gram-negative bacteria. Omiganan pentahydrochloride is able to interact with the bacterial cell membrane, causing the destruction of the cell membrane and the death of the bacteria. Omiganan pentahydrochloride can be used for the study of antimicrobial activity against pathogens commonly associated with catheter-associated infections, including strains with drug-resistant phenotypes .
    Omiganan pentahydrochloride
  • HY-173478
    OSUAB-0284

    		Topoisomerase Bacterial Antibiotic Infection
    OSUAB-0284 is a bacterial topoisomerase inhibitor. OSUAB-0284 has significant anti-staphylococcal activity, especially against methicillin-resistant Staphylococcus aureus (MRSA). OSUAB-0284 exerts its antibacterial effect by inhibiting bacterial topoisomerase. OSUAB-0284 can be used to study infections caused by drug-resistant bacteria such as MRSA .
    OSUAB-0284
  • HY-19234
    FK-041

    		Antibiotic Bacterial Penicillin-binding protein (PBP) Beta-lactamase Infection
    FK-041 is an orally active cephalosporin antibiotic with high affinity for penicillin-binding proteins (PBPs). FK-041 exhibits broad-spectrum antibacterial activity, exerting potent antibacterial effects against Gram-positive bacteria, most Gram-negative bacteria, anaerobes, and so on. FK-041 also shows good efficacy against some drug-resistant strains such as penicillin-resistant Streptococcus pneumoniae. FK-041 is an antibacterial agent and can be used in the research of infectious diseases .
    FK-041
  • HY-146811
    HSGN-94

    		Bacterial Inflammation/Immunology
    HSGN-94 is a potent antimicrobial agent with lipoteichoic acid (LTA) biosynthesis inhibition. HSGN-94 inhibits drug-resistant Gram-positive bacteria with MIC values of 0.25-2 μg/mL. HSGN-94 inhibits biofilm formation of MRSA and Vancomycin-resistant Enterococci. HSGN-94 also inhibits pro-inflammatory cytokines, exhibits in vivo efficacy in an MRSA murine wound infection model .
    HSGN-94
  • HY-116271
    Sperabillin C

    		Antibiotic Bacterial Infection
    Sperabillin C is an antibacterial antibiotic with activity against both Gram-negative and Gram-positive bacteria, including resistant strains of Pseudomonas aeruginosa and Staphylococcus aureus .
    Sperabillin C
  • HY-A0256R
    Clavulanic acid (Standard)

    		Beta-lactamase Reference Standards Antibiotic Bacterial Infection Inflammation/Immunology
    Clavulanic acid (Standard) is the analytical standard of Clavulanic acid. This product is intended for research and analytical applications. Clavulanic acid is a naturally occurring powerful bacterial β-lactamases inhibitor for research of infections caused by bacteria, including infections of the ears. Clavulanic acid is active against a wide spectrum of gram-positive and gram-negative bacterias[1].
    Clavulanic acid (Standard)
  • HY-162959A
    BWC0977 formic

    		Bacterial Topoisomerase DNA/RNA Synthesis Infection
    BWC0977 formic is an antibacterial agent that inhibits bacterial DNA replication via inhibition of DNA gyrase and topoisomerase IV. BWC0977 formic exhibits a minimum inhibitory concentration (MIC90) of 0.03-2 µg/mL against MDR (Multi-Drug Resistant) Gram-negative bacteria .
    BWC0977 formic
  • HY-P11102
    Temporin-SHa

    		Bacterial Fungal HIV Parasite Infection Cancer
    Temporin-Sha is an antibacterial peptide with extensive biological activity. Temporin-Sha exhibits broad-spectrum antibacterial activity (e.g., against L. ivanovii, MIC = 6.25 μM), and is effective against Gram-negative bacteria (such as Escherichia coli, MIC = 10 μM), including drug-resistant strains (such as Methicillin (HY-121544)-resistant Staphylococcus aureus). Temporin-Sha also has inhibitory effects on Candida albicans (MIC = 25 μM), Saccharomyces cerevisiae (MIC = 12 μM), the pre-flagellated and non-flagellated forms of Leishmania infantum (IC50 = 5-20 μM), and Trypanosoma cruzi (IC50 = 17 μM). Temporin-Sha exhibits antiviral activity against HSV-1 and has anti-cancer effects (cytotoxicity against breast cancer cells MCF-7 and lung cancer cells H460, etc.) .
    Temporin-SHa
  • HY-143326
    Antibacterial agent 83

    		Bacterial Infection
    Antibacterial agent 83 (compound 17h) displays potent antibacterial activity against various vancomycin-resistant Enterococcus faecalis (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). Antibacterial agent 83 can significantly reduce the biofilm formation of MRSA and exhibited promising selectivity. Antibacterial agent 83 is metabolically stable in human liver microsomes .
    Antibacterial agent 83
  • HY-178952
    Anti-infective agent 12

    		Bacterial Infection
    Anti-infective agent 12 (Compound A09) is a competitive inhibitor of type I signal peptidease (SPase I), with an IC50 of 4.475 μM and a Kd of 16.3 μM. Anti-infective agent 12 has the ability to disrupt bacterial membranes and remove biofilms. Anti-infective agent 12 exhibits potent bactericidal activity against Gram-positive bacteria, with MIC values of 4, 4, 8, and 8 μg/mL for Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, and Streptococcus suis, respectively. Anti-infective agent 12 remains effective against multi-drug resistant strains, but has weaker activity against Gram-negative bacteria (such as Escherichia coli and Salmonella), with MIC values > 64 μg/mL. Anti-infective agent 12 has low hemolytic activity and shows significant efficacy in mouse skin infection models .
    Anti-infective agent 12
  • HY-N15059
    Cissetin

    		Bacterial Infection
    Cissetin shows activity against Gram-positive bacteria, including drug-resistant strains .
    Cissetin
  • HY-117742
    DA-7867

    		Bacterial Infection
    DA-7867 is an antibacterial compound with activity against a wide range of bacteria, including drug-resistant bacteria. DA-7867 shows promising antibacterial activity against some clinically important pathogens, including drug-resistant bacteria. It is an amide analog of Tedizolid (HY-14855), reflecting the potential use of tetrazoles in the development of new antibacterial agents .
    DA-7867
  • HY-122073
    Furalazine

    		Bacterial Infection
    Furalazine is an antimicrobial agent. Furalazine shows activity against drug-resistant strains of cholera bacteria. Furalazine has the potential for the research of cholera .
    Furalazine
  • HY-139863
    Antibacterial agent 62

    		Bacterial Infection
    Antibacterial agent 62 is a novel redox cycling antituberculosis chemotype with potent bactericidal activity against growing and nutrient-starved phenotypically drug-resistant nongrowing bacteria.
    Antibacterial agent 62
  • HY-N14520
    Pacidamycin 4N

    		Bacterial Infection
    Pacidamycin 4N is a Pacidamycin antibiotic. Pacidamycin 4N has the activity against Pseudomonas aeruginosa with MIC of 4-16 μg/mL. it has no effect on other Gram-negative bacteria and Gram-positive bacteria, and no effect on drug-resistant pseudomonas aeruginosa .
    Pacidamycin 4N
  • HY-P10411
    BING

    		Bacterial Infection
    BING is an antimicrobial peptide that can be isolated from Japanese medaka fish. BING shows a broad-spectrum toxicity against pathogenic bacteria including drug-resistant strains. BING induces a deregulation of periplasmic peptidyl-prolyl isomerases in gram-negative bacteria, and reduces the RNA level of cpxR, which plays a crucial role in the development of antimicrobial resistance .
    BING
  • HY-146595
    FtsZ-IN-1

    		Bacterial Infection
    FtsZ-IN-1 is a potent FtsZ inhibitor with quinolinium ring. FtsZ-IN-1 has stronger antibacterial activity against Gram-positive bacteria with MICs of 0.5-8 μg/mL. FtsZ-IN-1 significantly causes cell elongation of B. subtilis by enhancing FtsZ polymerization. FtsZ-IN-1 exhibits low hemolytic toxicity and low tendency to induce agent resistance. FtsZ-IN-1 has against drug-resistant bacteria activity .
    FtsZ-IN-1
  • HY-P10540
    Pantinin-2

    		Bacterial Infection
    Pantinin-2 is a cysteine-free toxic peptide found in the emperor scorpion (paninus imperator). Pantinin-2 has high activity against Gram-positive bacteria but weak activity against Gram-negative bacteria. Pantinin-2 also exhibits activity against Candida tropicalis and has relatively mild hemolytic activity against human erythrocytes. Pantinin-2 can be used in the development of antimicrobial drugs for drug-resistant pathogens .
    Pantinin-2
  • HY-W353258R
    Moxifloxacin hydrochloride monohydrate (Standard)

    BAY 12-8039 monohydrate (Standard)

    		 Reference Standards Antibiotic Topoisomerase Bacterial Infection
    Moxifloxacin hydrochloride (BAY 12-8039) monohydrate (Standard) is the analytical standard of Moxifloxacin hydrochloride monohydrate. This product is intended for research and analytical applications. Moxifloxacin hydrochloride monohydrate is a blood-brain barrier-permeable, orally active topoisomerase II/IV inhibitor and a fluoroquinolone antibiotic. Moxifloxacin hydrochloride monohydrate disrupts bacterial DNA replication, transcription, repair and chromosome segregation processes. Moxifloxacin hydrochloride monohydrate exhibits activity against Gram-positive bacteria, Gram-negative bacteria, anaerobes, atypical pathogens, drug-resistant respiratory pathogens, Mycobacterium tuberculosis, mycoplasmas and Ureaplasma urealyticum.
    Moxifloxacin hydrochloride monohydrate (Standard)
  • HY-P3349
    c[Arg-Arg-Arg-Arg-Nal-Nal-Nal]

    		Bacterial Infection
    c[Arg-Arg-Arg-Arg-Nal-Nal-Nal] (Compound 9C) shows broad-spectrum activity against drug-resistant Gram-positive and Gram-negative bacteria, with MICs of 3.1, 3,1, 12.5, and 25 μg/mL for MRSA (ATCC BAA-1556), S. aureus (ATCC 29213), P. aeruginosa (ATCC 27883), and E. coli (ATCC 25922), respectively .
    c[Arg-Arg-Arg-Arg-Nal-Nal-Nal]
  • HY-P3348
    c[Arg-Arg-Arg-Arg-Dip-Dip-Dip]

    		Bacterial Infection
    c[Arg-Arg-Arg-Arg-Dip-Dip-Dip] (Compound 8C) shows broad-spectrum activity against drug-resistant Gram-positive and Gram-negative bacteria, with MICs of 3.1, 3,1, 12.5, and 12.5 μg/mL for MRSA (ATCC BAA-1556), S. aureus (ATCC 29213), P. aeruginosa (ATCC 27883), and E. coli (ATCC 25922), respectively .
    c[Arg-Arg-Arg-Arg-Dip-Dip-Dip]

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: